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Abstract 
Background: Women receiving chemotherapy treatment for breast cancer may experience problems with their 
memory and attention (cognition), which is distressing and interferes with quality of life. It is unclear what causes or 
contributes to the problems they report: psychological distress, fatigue, coping style, or specific biological changes for 
example to pro inflammatory cytokines. Research shows however, that approximately a third of women with breast 
cancer perform poorly on tests of cognition before commencing chemotherapy. We aimed to examine the accept‑
ability and relevance of pre‑surgical assessments (bloods, brain imaging, cognitive tests and self‑report question‑
naires) when investigating the phenomenon of ‘chemo‑brain’ and investigate whether inflammatory markers mediate 
chemotherapy‑induced neuropsychological impairments in women treated for breast cancer.
Methods: Women with early stage breast cancer completed neuropsychological and quality of life assessments at T1 
(pre‑surgery), T2 (post‑surgery before chemotherapy) and T3 (6 months later). Blood cytokine levels were measured at 
the same time points and brain imaging was performed at T1 and T3.
Results: In total, 14/58 women participated (8 chemotherapy, 6 non‑chemotherapy). Prior to the start of chemo‑
therapy a decline in cognitive performance compared to baseline was observed in one participant. At T3 women who 
received chemotherapy reported poorer quality of life and greater fatigue. Increases in soluble tumour necrosis factor 
receptor II (sTNFRII), interleukin‑6, interleukin‑10 and vascular endothelial growth factor occurred post chemotherapy 
only. Levels of sTNFRII were inversely correlated with grey matter volume (GMV) of the right posterior insula in both 
groups. At T3, the chemotherapy group displayed a greater reduction in GMV in the subgenual and dorsal anterior 
cingulate, and the inferior temporal gyrus.
Conclusions: Pre‑operative recruitment to the study was challenging; however, the lack of significant changes in 
blood cytokine levels and neuropsychological tests at T2 implies that post surgery may be a valid baseline assess‑
ment, but this needs further investigation in a larger study. The preliminary results support the hypothesis that chem‑
otherapy induced fatigue is mediated by a change in peripheral cytokine levels which could explain some symptoms 
of ‘chemo brain’ experienced by patients.
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Background
‘Chemo-brain’ is a term used for cognitive impairment 
such as memory and attention problems, following 
chemotherapy. Previous neurological studies show cog-
nitive dysfunction in 15–70  % of patients treated with 
chemotherapy (Ahles et  al. 2002; Jim et  al. 2009; Her-
melink et al. 2007; Jenkins et al. 2006; Wefel and Schagen 
2012). The wide variance is partly due to the use of dif-
ferent neuropsychological tests between studies, different 
reference data and performance cut offs for classifying 
test results (Shilling et al. 2006). According to the Inter-
national Cognition and Cancer Task Force (ICCTF), 
studies conducted to date show a frontal subcortical pro-
file with the following domains affected: learning and 
memory, processing speed and executive function (Wefel 
et al. 2011). While chemotherapy may be a key contribu-
tor, it is not the sole cause of cognitive impairment as a 
third of women perform poorly on cognitive tasks follow-
ing surgery but prior to starting adjuvant therapies (Her-
melink et al. 2007; Ahles et al. 2008). Poor performance 
has been associated with cancer related stress similar to 
that observed in post-traumatic stress disorder (Reid-
Arndt and Cox 2012; Hermelink et  al. 2015). Whatever 
the underpinning causal factors, the phenomenon of 
‘chemo brain’ continues to cause problems for patients 
and impact negatively on their quality of life (QoL).
The mechanisms underlying chemo-brain are not clear 
but suggestions include stress and coping styles (Reid-
Arndt and Cox 2012), direct neurotoxic injury, telomere 
shortening, oxidative stress, cytokine dysregulation, 
oestrogen-mediated effects, and genetic polymorphisms 
(Walker et al. 2012). Chemotherapy drugs, which because 
of their molecular size are mostly unable to cross the 
blood–brain-barrier can cause toxicity to the brain indi-
rectly via cytokines that do cross over. Evidence sug-
gests that elevated levels of peripheral cytokines may be 
related to cognitive problems in cancer patients (Ahles 
and Saykin 2007; Janelsins et al. 2012; Wang et al. 2015). 
Studies employing magnetic resonance imaging (MRI) 
and functional MRI (fMRI) techniques demonstrate both 
hypo- and hyper-activation in the absence or presence of 
cognitive dysfunction. Imaging studies have documented 
structural changes to the brain, including reduction in grey 
matter volume (GMV) and white matter microstructural 
damage (Wefel and Schagen 2012; McDonald et al. 2012). 
Alterations are noted from 1 month to 21 years post chem-
otherapy (McDonald et al. 2012; Koppelmans et al. 2011). 
However, some structural differences may already be pre-
sent before starting treatment (Scherling et al. 2012) and 
more recently symptoms of fatigue have been associated 
with the observed abnormalities (Menning et al. 2015).
One of the criticisms of research investigating chemo-
brain is the lack of a preoperative baseline assessment in 
order to be confident that any changes found post treat-
ment are not confounded by surgery (e.g., type, length of 
general anaesthesia, stress). This is especially important 
when investigating changes to levels in cytokines and 
brain imaging. To the best of our knowledge, this is the 
first study in breast cancer patients to combine neuroim-
aging, blood tests, cognitive testing and questionnaires 
reporting cognitive symptoms, fatigue, QoL, and anxi-
ety/depression before and after surgery, and following a 
course of chemotherapy.
The primary objective was to explore the acceptability 
and feasibility of conducting a comprehensive assessment 
(neuropsychological assessment, blood tests and MRI 
scan) prior to breast cancer surgery. Secondary objectives 
were: (1) to examine whether changes occur in cytokine 
levels following surgery and chemotherapy compared to 
baseline (pre-surgery) and whether these correlate with 
changes in subjective cognitive performance, fatigue 
and imaging data, and (2) to investigate using advanced 
imaging techniques if chemotherapy is associated with 
quantifiable structural brain changes and if this is related 
to changes in cognitive function and/or magnitude of 
inflammatory response to chemotherapy.
Methods
Study design and participants
This was a prospective, longitudinal study involving 
objective and subjective measures of cognitive function 
and QoL, together with blood cytokine analysis prior to 
surgery (T1), following surgery and before adjuvant treat-
ment (T2) and approximately 6 months later at comple-
tion of chemotherapy treatment (T3). Brain imaging with 
highly sensitive MRI techniques was conducted at T1 and 
T3 only.
Participants were women aged 47–61 years diagnosed 
with early stage invasive breast cancer (who may or may 
not require chemotherapy treatment) and those with 
ductal carcinoma in situ. Patient identification and eligi-
bility screening took place in the breast cancer Multidis-
ciplinary Team Meetings and clinics of the Brighton and 
Sussex University Hospitals NHS Trust. Those eligible 
were given an information pack and letter of introduc-
tion following their surgical consultation and contacted 
the research team if they wanted to participate. The 
study was approved by the London Camberwell St Giles 
National Regional Ethics Committee (13/LO/0164) and 
written consent was obtained from all participants.
Procedures and measures
Participant characteristics and treatment-related data 
were collected at baseline by interview and via medical 
records. Premorbid intelligence was estimated with the 
National Adult Reading Test (Nelson and Wilson 1991; 
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Crawford et al. 1989). At T3 women were asked to pro-
vide feedback about study participation, specifically the 
timing of the assessments, which were conducted at 
the University of Sussex and took approximately 3  h to 
complete.
Neuropsychological assessments
A comprehensive test battery was selected according to 
the recommendations of the International Cognition in 
Cancer Task Force (ICCTF) to assess cognitive function 
(Wefel et  al. 2011) using the following 6 measures: Rey 
Auditory Verbal Learning Test (RAVLT) (Schmidt 1996), 
Letter–Number Sequencing (LNS) (Wechsler 1997), 
Stroop Colour and Word Test (Golden 1978); Controlled 
Oral Word Association test (COWAT) (Benton et  al. 
1994; Shao et al. 2014), Double Letter Cancellation Task 
(DLCT) (Lezak 2012), and the Grooved Pegboard (GP) 
(Lafayette 1998). Tests were administered in the same 
order at each time point and alternate versions used 
where possible to minimise practice effects (“Appendix 
1”).
Patient reported outcomes (PROs)
Quality of life was measured with the Functional Assess-
ment of Cancer Therapy-Breast (FACT-B) version 4 
(Brady et  al. 1997). This is a 37-item self-administered 
questionnaire with 4 subscales: physical well-being 
(PWB), social well-being (SWB), emotional well-being 
(EWB), functional well-being (FWB), and a breast can-
cer-specific subscale (BCS). Each item has a 5-point 
response scale ranging from 0 (not at all) to 4 (very 
much). Higher total scores indicate better function-
ing. The 13-item Fatigue subscale version 4 was used to 
measure perceived fatigue over the last week (Yellen et al. 
1997). Perceived cognitive function was assessed with the 
FACT-Cognitive function (FACT-Cog) version 3 (Wag-
ner et  al. 2009). This scale has 37 items for 4 subscales: 
perceived cognitive impairments (PCI), perceived cog-
nitive abilities (PCA), deficits observed or commented 
on by others (Oth), and impact on QoL (CogQOL). The 
10-item Trauma Screening Questionnaire (TSQ) was 
included to screen for symptoms of traumatic stress 
(Brewin et al. 2002).
Blood collection and biological specimens
Serum was collected from clotted peripheral blood col-
lected at each time point by venepuncture into silica 
containing vacutainers (Becton–Dickinson, Oxford, 
UK). Serum levels of Interleukin-6 (IL-6), IL-10, mono-
cyte chemotactic protein-1 (MCP-1), brain-derived neu-
rotrophic factor (BDNF) and soluble TNF receptor II 
(sTNFRII) were measured by Quantikine high sensitiv-
ity ELISAs (R&D systems, Minneapolis, USA). Vascular 
endothelial growth factor (VEGF) was measured using 
Duoset antibodies (R&D systems, Minneapolis, USA) 
according to manufacturer’s instructions. Haemoglobin 
levels were recorded separately as part of a participant’s 
clinical assessment by the clinical team.
MRI acquisition
All imaging was performed using a research optimised 
1.5T scanner (Siemens Magnetom Avanto) with a 
32-channel head coil. Each session lasted approximately 
1 h and included the following scans: (1) a T1-weighted 
high-resolution (MPRAGE) volumetric scan, for measur-
ing white and grey matter regional volume changes; (2) 
a diffusion-tensor imaging (DTI) sequence (60 direc-
tions, maximum b factor  =  1200  s/mm2); (3) a serial 
gradient echo echo-planar imaging (EPI) scan to record 
resting-state (RS) fMRI data (approximately 7  min); (4) 
a 3D gradient echo sequence, which collects a series of 
magnetization transfer (MT)-weighted volumes with 
differing degrees of MT-weighting; (5) a T1-mapping 
sequence, and (6) a B1-mapping sequence. During the 
fMRI scan, subjects were instructed to lie still, with their 
eyes closed, without falling asleep. Only the results from 
the volumetric assessment are reported here.
Statistical methods
Demographical and clinical characteristics for all patients 
are summarised and stratified by chemotherapy expo-
sure status. The feasibility study was not powered for 
comparison between groups on the objective cogni-
tive tasks; results are presented as changes across time 
by determining the proportion of women with ≥2 test 
scores at or below 1.5 SDs, or ≥1 test score at or below 
2.0 SDs from the normative mean, or both (Wefel et al. 
2011). Also the reliable change index (RCI) with a correc-
tion for observed practice effects was calculated for each 
measure (Sawrie et  al. 1996). The RCI is a well-known 
method used to determine if a change is reliable rather 
than simply due to test measurement error (i.e. practice 
effects), accounting for differences between pre- and 
post-test variance. An RCI criterion of ≥1.96 (95 % con-
fidence interval) was utilized. An RCI was calculated for 
a selection of cognitive measures for each participant 
using the baseline and T2 and baseline and T3 data of an 
age and intelligence matched comparative group of con-
trol subjects and categorized as ‘Declined’, ‘Improved’, or 
‘Unchanged’ (Jacobson and Truax 1991).
Changes in patient reported outcomes for the FACT-B 
and the Fatigue subscale were calculated. The trial out-
come index (TOI) used for the FACT-B is an efficient 
summary index of physical/functional outcomes, and 
a common endpoint used in clinical trials (Eton et  al. 
2004). It is the sum of the scores of the 28 items included 
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in the PWB, FWB and BCS (range 0–112). A change of at 
least seven points from baseline TOI score for FACT-B 
is considered a relevant clinically minimal important dif-
ference, and for the Fatigue subscale it is a change of ≥3 
points (Yost and Eton 2005). A total TSQ score of ≥6 was 
considered to be an indication of the presence of trau-
matic stress (Brewin et al. 2002).
To assess the relationship between cytokine levels and 
cognitive impairment during chemotherapy, serum levels 
of sTNFRII, IL-6, VEGF, IL-10, BDNF and MCP-1 were 
measured. Significance was assessed using a one-tailed 
Mann–Whitney test using GraphPad Prism version 5 
(GraphPad Software, La Jolla California USA).
The MPRAGE scans from all patients at T1 and T3 
were analysed using voxel-based morphometry (VBM) 
(Ashburner and Friston 2000; Ashburner and Friston 
2005). VBM is an image analysis technique which is used 
to identify regional difference in GMV between groups 
or to investigate the correlation between local GMV and 
other variables of interest (“Appendix 2”). The technique 
relies on the accurate alignment of images from differ-
ent individuals into a common brain space, in order to 
achieve a perfect correspondence between a specific 
set of image coordinates and the same anatomical brain 
structure across subjects. The images are then seg-
mented into separate tissues to provide “maps” of grey 
matter, white matter and volume. Statistical compari-
sons can then be carried out to highlight the areas of the 
brain where significant results are found. For the pur-
pose of this paper, data were analysed using the VBM8 
toolbox (http://dbm.neuro.uni-jena.de/vbm/) for SPM8 
(Wellcome Trust Centre for Neuroimaging, http://www.
fil.ion.ucl.ac.uk/spm/software/spm8/). The images were 
therefore segmented and normalised to Montreal Neu-
rological Institute (MNI) space and segmented, then 
they were spatially filtered with a 3D Gaussian kernel 
(full width at half maximum = 8 mm3). The purpose of 
this final step, also known as ‘smoothing’, is to compen-
sate for residual inter-individual differences and to make 
the data more normally distributed in preparation for 
statistical analysis. To explore changes in GMV induced 
by chemotherapy, a two-way between subject ANOVA 
model in SPM8 was used, within the framework of 
the general linear model. In a within-subject design, 
we modelled the effect of group (chemotherapy vs no 
chemotherapy) and the effects of session (T1 vs. T3). 
We also modelled the interaction between these two fac-
tors. A linear regression model was used to investigate 
the presence of any association between GMV at T3 and 
inflammatory factors. As this is an exploratory study, we 
accepted as significant p values inferior to 0.005, in clus-
ters of 100 or more voxels.
Results
Patient characteristics
The research nurse approached 58 potentially eligi-
ble women for the study in clinic between May 2013 
and April 2014; 9 were ineligible and 14/49 (29  %) par-
ticipated. There was no study attrition at follow-up. The 
main reason for nonparticipation was lack of time; many 
women worked and were reluctant or unable to fit in the 
lengthy test procedures before surgery.
Table  1 displays participants’ characteristics. Median 
time between T1 and surgery was 8  days (range 2–22). 
Eight women were treated with chemotherapy (CT) and 
all received an anthracycline containing regimen. Pre-
operative levels of haemoglobin were in the normal range 
(≥120 g/L) for all participants; 4/8 CT women were anae-
mic at T3. Four women were postmenopausal at baseline 
and seven experienced a treatment-induced menopause. 
Women in the no-chemotherapy group (NCT) had 
higher premorbid IQ (p = 0.015). At T3 86 % of women 
had received or were scheduled for radiotherapy and 
71 % were prescribed endocrine therapy.
Cognitive and PRO results
Outcomes of the neuropsychological tests and PROs by 
treatment group for each time point are listed in Table 2. 
A difference in performance compared to normative 
values on the objective tests were observed at T3 (after 
treatment completion) in two participants (one in each 
treatment group). The proportion of each group showing 
reliable decline or reliable improvement on the RAVLT, 
Stroop and LNS was calculated for T2 and T3. Reli-
able decline was observed in 1 CT patient; however this 
was prior to the start of chemotherapy (T2). No reliable 
improvement was observed for any participant.
During the study six patients [5 CT (63  %); 1 NCT 
(17 %)] experienced a decrease at T3 from baseline of ≥7 
points in TOI of the FACT-B (i.e. reporting lower health-
related QoL). Similar findings occurred for fatigue; 6 (75 %) 
CT and 2 (33 %) NCT. Levels of fatigue correlated with the 
subscale PCI from the FACT Cog (r = 0.848; p < 0.001). 
Improvement in health-related QoL was reported by four 
women (two in each group), and a significant reduction in 
fatigue for three participants (2 CT; 1 NCT). High levels 
of stress were reported by five women (3 CT, 2 NCT) at 
baseline, and two women (one in each group) post-surgery 
(T2). Stress levels remained high across all time points for 
one CT patient. Participants expressed only positive com-
ments about the study; many found it useful to gauge how 
they were functioning through treatments. However, they 
reported that the pre-operative period was stressful and 
time pressured, and could understand why many women 
may not want to participate.
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Cytokines results
All cytokine levels in NCT patients were unchanged 
across time and no changes were observed in CT patients 
between T1 and T2 (Fig.  1). In CT patients, significant 
elevations of sTNFRII (p  =  0.0041), IL-6 (p  =  0.0298) 
and VEGF (p  =  0.013) were observed at T3 relative to 
NCT (Fig. 1a–c). An increase in IL-10 was also detected 
but this did not reach significance (Fig. 1d), whereas no 
changes were observed between the patient groups at 
any of the time points for MCP-1 and BDNF (Fig. 1e, f ). 
Correlations with patient-reported fatigue and perceived 
cognitive function (PCI, PCA) were not significant.
Neuroimaging results
Table 3 summarizes the location of grey matter clusters 
where a significant group-by-session interaction was 
found with respect to GMV. VBM analysis showed a sig-
nificant group-by-session interaction, with CT patients 
showing larger volumetric reductions in the sub-genual 
and anterior midcingulate cortex (aMCC) as well as the 
inferior temporal gyrus (ITG) compared to NCT (Fig. 2; 
Table  3). Significant correlations were also found at T3 
between GMV of the posterior insula and sTNFRII, and 
between cerebellar lobule IX volume (bilaterally) and 
IL-6 (Fig. 3).  
Discussion
Pre-operative recruitment to a non-clinical breast can-
cer trial is challenging, and lengthy study procedures are 
not feasible for studies with limited recruitment time-
lines. A key factor in recruitment was timing. Time con-
straints and research burden were the main reasons for 
nonparticipation in our feasibility study. A reluctance to 
participate in research between breast cancer diagno-
sis and surgery has been reported elsewhere (Hepworth 
et al. 2011; Ashley et al. 2012). Another reason for declin-
ing the study was anxiety about the scheduled breast 
surgery. This is not uncommon and both diagnostic (e.g. 
excisional biopsy) and curative breast cancer surgery (e.g. 
mastectomy) are emotionally taxing producing height-
ened distress (Montgomery et al. 2003; Poole 1997). For 
the majority of women in our study stress levels reduced 
significantly following surgery. Interestingly, our cytokine 
analyses showed no significant change before and after 
surgery further supporting the case for approaching 
breast cancer patients for these types of studies in the 
post-operative period.
Our secondary objectives were met in part; there were 
no significant differences in QoL, levels of fatigue and 
perceived memory problems for women from pre to 
post-surgery. However at 6  months those who received 
chemotherapy reported more memory problems, greater 
fatigue and poorer QoL. Additionally, self-reported 
Table 1 Demographics and clinical characteristics
AC doxorubicin and cyclophosphamide, BMI body mass index, FEC 75 
fluorouracil, epirubicin (75 mg/m2) and cyclophosphamide, FEC-T fluorouracil, 
epirubicin, cyclophosphamide and docetaxel, FSIQ full scale intelligence 
quotient, G-CSF granulocyte-colony stimulating factor, Hb haemogloblin, HRT 
hormone replacement therapy, SD standard deviation, WLE wide local excision
* p < 0.05
a Derived from the National Adult Reading Test
b One participant had an ungraded tumour due to unusual presentation






 Mean (SD) 52.6 (3.9) 50.2 (2.3)
 Range 50–61 47–53
Partner
 Yes 4 5
Education
 Higher 3 4
 Further 2 1
 Secondary 3 1
FSIQa
 Mean (SD)* 111.1 (7.4) 120.8 (4.5)
 Range 106–123 112–124
Employed
 Full‑time 5 4
 Part‑time 3 2
Cancer stage*,b
 I 0 4
 II 1 1
 III 7 0
Type of surgery
 Mastectomy 2 1
 WLE 6 5
Node sampling
 Yes 8 6
Chemotherapy regimen
 AC 1 –
 FEC 75 2 –
 FEC‑Tc 5 –
Herceptin
 Yes 2 –
Radiotherapy
 Yes 7 5
Endocrine therapy by T3
 Yes 3 6
Postmenopausal at baseline
 Yes 3 2
Prior HRT
 Yes 2 1
Baseline Hb level (g/L)
 Mean (SD) 135.4 (10.9) 133.8 (7.6)
 Range 120–151 126–145
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problems with memory and attention were associated 
with reported levels of fatigue, which may give reassur-
ance to some patients that there was an explanation for 
their symptoms. The primary purpose of the study was to 
establish the feasibility of pre-operative assessment, so it 
was not powered to examine differences between groups 
for tasks of memory and attention, but individual change 
analysis showed most women performed well.
There were no significant changes in cytokines pre and 
post-surgery. Significant increases were observed in the 
serum levels of sTNFRII, IL-6 and VEGF following chem-
otherapy. These findings were supportive of prior studies 
which hypothesised that chemotherapy induced fatigue 
may be mediated by changes in inflammatory cytokines 
(Ahles and Saykin 2007). We did not observe any signifi-
cant associations between increased cytokine levels and 
fatigue or subjective cognitive complaints most prob-
ably due to the small sample size; however such obser-
vations have been made by other researchers, (Bower 
et al. 2011; Ganz et al. 2013). In one cohort study, expo-
sure to chemotherapy (i.e. ≤3  months after last cycle) 
was linked to elevations in sTNFRII, with the strongest 
associations between sTNFRII and fatigue in the chemo-
therapy exposed patients (Bower et al. 2011). Ganz et al. 
(2013) confirmed at follow-up in the same sample that 
higher baseline sTNFRII levels were significantly corre-
lated to increased self-reported memory complaints but 
not to objective neuropsychological test results. These 
Table 2 Cognitive performance (raw test scores) at each time point for CT and NCT groups: mean (SD)
RAVLT Rey Auditory Verbal Learning Test, COWAT Controlled Word Association Test, FACT-B Functional Assessment of Cancer Therapy-Breast, FACT-F Functional 
Assessment of Cancer Therapy-Fatigue, FACT-Cog Functional Assessment of Cancer Therapy-Cognitive function, PCA perceived cognitive abilities, PCI perceived 
cognitive impairment, Oth deficits observed or commented on by others, CogQOL impact on quality of life, SD standard deviation, TSQ Trauma Screenings 
Questionnaire
Chemotherapy (n = 8) No chemotherapy (n = 6)
T1 T2 T3 T1 T2 T3
RAVLT
 Supraspan (0–15) 7.3 (2.3) 7.3 (2.7) 7.2 (2.2) 10.3 (3.3) 9.0 (3.0) 9.4 (3.0)
 Total score (0–75) 56.0 (9.1) 52.4 (12.3) 54.2 (9.8) 62.7 (7.9) 61.3 (9.8) 61.8 (8.6)
 Delayed score (0–15) 12.5 (2.8) 11.3 (2.4) 11.3 (2.4) 11.5 (1.5) 12.7 (2.4) 12.3 (2.0)
Double letter cancellation
 Time (s) 185.0 (32.1) 174.3 (20.1) 179.4 (69.5) 176.7 (26.8) 163.7 (30.3) 160.0 (30.4)
 Total score 69.4 (3.3) 70.9 (2.1) 69.5 (2.9) 72.0 (3.3) 72.8 (2.6) 72.3 (3.2)
Letter number sequencing
 Total score 10.3 (3.2) 10.6 (3.7) 10.8 (3.3) 12.8 (3.0) 12.8 (2.6) 13.2 (3.0)
COWAT
 Total score 56.4 (15.5) 54.0 (16.6) 54.4 (15.0) 55.2 (9.9) 54.0 (6.5) 55.2 (9.0)
Stroop Colour Word Test
 Word card 101.1 (15.4) 101.0 (18.0) 97.8 (20.0) 113.2 (14.3) 114.7 (16.5) 113.8 (17.3)
 Colour card 78.0 (11.7) 77.0 (15.1) 77.0 (11.3) 87.3 (12.8) 86.0 (9.1) 87.3 (14.7)
 Colour‑word card 45.3 (6.6) 47.1 (7.6) 47.5 (6.9) 52.0 (14.8) 55.8 (9.7) 56.3 (9.9)
 Interference score 1.5 (4.8) 3.8 (7.2) 4.7 (8.1) 2.9 (12.0) 6.9 (8.6) 7.1 (8.1)
Grooved Pegboard
 Dominant hand: time (s) 67.1 (7.2) 65.7 (9.3) 66.2 (7.5) 63.3 (6.6) 59.0 (5.7) 61.2 (6.8)
 Dominant hand: total 92.4 (7.4) 90.9 (9.3) 91.4 (7.7) 88.3 (6.6) 84.2 (5.7) 86.3 (6.8)
 Non‑dominant hand: time (s) 76.4 (8.7) 75.4 (7.6) 75.4 (7.4) 78.0 (10.5) 66.8 (4.2) 70.4 (9.5)
 Non‑dominant hand: total 101.4 (8.7) 100.4 (7.6) 100.5 (7.5) 103.5 (9.8) 91.8 (4.2) 95.6 (9.4)
FACT‑B (0–112) 105.6 (7.8) 101.8 (17.5) 101.6 (12.9) 115.4 (10.8) 112.3 (13.3) 116.0 (18.0)
FACT‑F (0–160) 114.6 (15.0) 111.8 (18.8) 107.5 (19.7) 128.9 (12.0) 125.6 (14.8) 127.2 (20.3)
FACT‑Cog
 PCI (0–72) 49.9 (14.4) 42.9 (15.8) 36.8 (14.0) 49.8 (8.4) 47.2 (15.7) 48.0 (11.9)
 PCA (0–28) 18.6 (4.3) 13.3 (4.8) 13.3 (5.6) 16.8 (6.2) 18.2 (5.7) 18.0 (6.4)
 Oth (0–16) 14.3 (2.9) 13.9 (2.9) 14.9 (1.9) 14.8 (2.4) 14.8 (1.5) 15.2 (1.2)
 CogQOL (0–16) 12.9 (3.8) 11.1 (2.9) 11.3 (3.8) 9.5 (5.4) 12.7 (1.8) 12.5 (4.0)
TSQ (0–10) 4.4 (2.5) 3.9 (2.2) 3.3 (1.3) 4.8 (2.5) 3.0 (2.8) 2.2 (1.9)
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results support our observation of significant sTNFRII 
elevation in chemotherapy exposed patient sera. The near 
uniform increase in sTNFRII elevation in CT but not 
NCT patients suggests that sTNFRII is a useful marker of 
peripheral cytokine alterations following chemotherapy.
A recent study also confirmed the association between 
pro inflammatory cytokines (higher concentrations of 
IL-6 and IL-1ß) and more severe self-perceived cogni-
tive disturbances (Cheung et  al. 2013). Other research 
suggests further that cytokines and inflammatory mark-
ers can give rise to a cluster of cancer-related symptoms 
including fatigue, depression and stress, which are asso-
ciated with cognitive changes (e.g. Bower et al. 2011; Lee 
et al. 2004; Meyers 2008). A comprehensive review noted 
that these symptoms are rarely controlled and concluded 
that the intermediary role of cytokines in post-chem-
otherapy cognitive impairment remains controversial 
(Ganz et al. 2013).
Research has shown neuroanatomical differences 
between breast cancer patients (pre-chemotherapy) and 
matched non-cancer controls, stressing the importance 
of the comparison group (Scherling et  al. 2012). In our 
Fig. 1 Levels of circulating cytokines are altered by treatment with chemotherapy. Serum was collected from breast cancer patients being treated 
with chemotherapy (CT) and those not undergoing chemotherapy (NCT). Serum levels of a sTNFRII, b IL‑6, c VEGF, d IL‑10, e MCP‑1 and f BDNF 
were measured. Data for eight CT patients and six NCT patients is shown as the mean ± SEM (*p < 0.05; **p < 0.01)
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study, a larger reduction in the volume of the sub-gen-
ual and dorsal anterior cingulate as well as the inferior 
temporal gyrus (ITG) was observed for the chemother-
apy group compared to the non-chemotherapy group. 
Sub-genual and dorsal aspects of the anterior midcin-
gulate cortex (aMCC) have previously been reported 
to show functional alterations following experimen-
tally-induced inflammation (Harrison et  al. 2009a, b). 
Interestingly, changes in subgenual cingulate function 
and volume have been repeatedly demonstrated in idi-
opathic depression (Mayberg et  al. 2005; Drevets et  al. 
1997). Furthermore, reductions in sub-genual cingulate 
reactivity to emotional stimuli also appears to mediate 
inflammation-induced mood change (Harrison et  al. 
2009a). Together, these findings suggest that post-chem-
otherapy cognitive changes may relate to subtle effects on 
mood and/or motivation and support our hypothesis that 
our observed grey matter changes may relate to chemo-
therapy-induced inflammation. The significance of our 
observed changes in ITG are less clear. The ITG’s primary 
function relates to visual object recognition and memory, 
however, a recent paper has reported greater atrophy of 
the right ITG in fatigued versus non-fatigued patients 
with multiple sclerosis (Rocca et al. 2014).
Relationships between circulating cytokine levels and 
regional brain volumes have been reported in breast can-
cer survivors. In one study of 20 breast cancer patients 
and 23 healthy controls, left hippocampal volumes were 
reduced significantly and IL-6 and TNF-α concentra-
tions elevated in the breast cancer group and lower left 
hippocampal volume was associated with higher cir-
culating TNF-α and lower IL-6 (Kesler et  al. 2013). In 
our study, circulating sTNFRII inversely correlated with 
GMV in the right posterior insula (across both groups). 
Insula is believed to provide a cortical representation of 
bodily physiological state including inflammatory status 
(Critchley and Harrison 2013) and activity changes have 
been repeatedly shown to correlate with inflammation-
induced fatigue (Harrison et al. 2009b, 2015). Finally, we 
Table 3 Grey matter volume results of the two-way ANOVA 
indicating the brain area, the spatial coordinates and the p 
value of the significant effect








Right inferior temporal gyrus 47 −20 −29 4.74 <0.001
Subgenual cingulate cortex 0 32 −6 4.38 <0.001
Right anterior midcingulate  
gyrus
8 29 22 4.53 <0.001
Fig. 2 Grey matter volume results: two‑way ANOVA. The areas of sig‑
nificant group‑by‑time interaction are highlighted, and overlaid onto 
a T1‑weighted template image. a 2 clusters in the cingulate cortex; b 
the inferior temporal gyrus cluster
Fig. 3 Grey matter volume results: correlations with cytokines. The 
solid coloured areas indicate the localisation of the significant cor‑
relation between grey matter volume and IL‑6 (a) or sTNFRII (b). The 
clusters are overlaid onto a T1‑weighted template image in standard 
space
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also observed a significant correlation between cerebellar 
lobule IX volume (bilaterally) and IL-6. Little is currently 
known about the functional role of this lobule, but it has 
been suggested to form part of the default mode network 
(Habas et al. 2009), a network central to off-task ‘resting’ 
brain activity. However, given the small sample size of the 
current study, the significance of these observed correla-
tions needs to be considered with caution and warrants 
further investigation.
In summary, the low acceptance rate showed that it is 
not feasible to recruit women for cognitive testing and 
brain imaging prior to breast cancer surgery. As there 
were few differences in patient reported outcomes, cog-
nitive tests or changes in blood cytokine levels before 
and after surgery, we can be cautiously confident that the 
period post-surgery but pre-chemotherapy is a pragmatic 
and valid baseline assessment time point. The hypoth-
esis that chemotherapy induced fatigue is mediated by a 
change in peripheral cytokine levels is supported by our 
pilot data and observed changes on brain scans, which 
may explain the symptoms often experienced by patients 
undergoing chemotherapy. A larger longitudinal study is 
now warranted to confirm these preliminary hypotheses 
and investigate whether some women are more suscep-
tible than others to fatigue. Future studies may consider 
pharmaceutical and non-pharmacological interventions 
to combat fatigue to help ameliorate the symptoms of 
‘chemo brain’.
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Appendix 1
See Table 4.
Table 4 Overview of neuropsychological tests
a Baseline (T1) only
b Alternate versions were used at each time point
c Two parallel sets of letters were used (C–F–L at T1 and T3, P–R–W at T2)
Test Ability measured Outcome measure
National Adult Reading Testa (Nelson and Wilson 1991; 
Crawford et al. 1989)
Premorbid intelligence Total correct responses
Rey Auditory Verbal Learning Testb (Schmidt 1996) Verbal learning, recall, and retention Supraspan (trial 1), total correct trials 1‑5, delayed recall 
(trial 7)
Grooved Pegboard (Lezak 2012; Lafayette 1998) Manual fine motor speed Completion time, total number pegs placed with 
dominant and nondominant hand
Letter–number sequencing (Wechsler 1997) Working memory capacity Total correct responses
Double letter cancellation task (Lezak 2012) Processing speed, attention Completion time, total number of correct responses
Stroop Colour and Word Test (Golden 1978) Cognitive flexibility, executive function Total correct for word‑reading, colour naming, and 
colour‑word reading task (45 s for each tasks)
Controlled Oral Word Association Testc (Benton et al. 
1994; Shao et al. 2014)
Language, executive function Total number of correct words produced within the 
given letter triad (1 min for each letter)
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Appendix 2
See Fig. 4.
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